NEW YORK, Nov. 16, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Adeptus Health securities (NYSE:ADPT): (1) from April 23, 2015 through November 16, 2015, both dates inclusive; and/or (2) pursuant and/or traceable to Adeptus Health’s secondary public offering on or about July 31, 2015. The lawsuit seeks to recover damages for Adeptus Health investors under the federal securities laws.
To join the Adeptus Health class action, go to http://rosenlegal.com/cases-789.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Adeptus Health was engaging in predatory billing practices, which exposed Adeptus Health to numerous risks and possible penalties, including civil and/or criminal sanctions, and exclusion from federal and/or state healthcare programs; (2) Adeptus Health’s financial statements had not been prepared in conformity with generally accepted accounting principles; and (3) contrary to representations about Adeptus Health’s practice of referring lower acuity patients to urgent care facilities, it routinely treated and excessively billed these patients. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 27, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-789.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
FDA Approves Mitapivat for Anemia in Thalassemia Patients
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 



